InflaRx Regains Compliance with Nasdaq Minimum Bid Price Requirement
InflaRx (NASDAQ: IFRX), a biopharmaceutical company focused on anti-inflammatory therapeutics, has successfully regained compliance with Nasdaq's minimum bid price requirement. The company maintained a closing bid price of $1.00 or higher for 10 consecutive business days from August 27 to September 10, 2025.
InflaRx specializes in developing inhibitors of the complement activation factor C5a and its receptor. Their key product is vilobelimab, an intravenous first-in-class anti-C5a monoclonal antibody, alongside INF904, an oral small molecule inhibitor. The company, founded in 2007, operates from offices in Jena and Munich, Germany, and Ann Arbor, Michigan.
InflaRx (NASDAQ: IFRX), una società biofarmaceutica focalizzata su terapie anti-infiammatorie, ha riacquistato con successo la conformità al requisito di prezzo minimo di Nasdaq. L'azienda ha mantenuto un prezzo di chiusura di $1,00 o superiore per 10 giorni lavorativi consecutivi dal 27 agosto al 10 settembre 2025.
InflaRx è specializzata nello sviluppo di inibitori del fattore di attivazione del complemento C5a e del suo recettore. Il loro prodotto chiave è vilobelimab, un anticorpo monoclonale anti-C5a somministrato per via endovenosa di prima classe, insieme a INF904, un inibitore orale di piccole molecole. L'azienda, fondata nel 2007, opera con uffici a Jena e Monaco di Baviera, in Germania, e ad Ann Arbor, nel Michigan.
InflaRx (NASDAQ: IFRX), una empresa biofarmacéutica centrada en terapias antiinflamatorias, ha logrado reponerse con éxito al requisito de precio mínimo de Nasdaq. La compañía mantuvo un precio de cierre de $1.00 o más por 10 días hábiles consecutivos desde el 27 de agosto hasta el 10 de septiembre de 2025.
InflaRx se especializa en desarrollar inhibidores del factor de activación del complemento C5a y de su receptor. Su producto clave es vilobelimab, un anticuerpo monoclonal anti-C5a administrado por vía intravenosa de primera clase, junto con INF904, un inhibidor oral de moléculas pequeñas. La empresa, fundada en 2007, opera desde oficinas en Jena y Múnich, Alemania, y Ann Arbor, Michigan.
InflaRx (NASDAQ: IFRX)는 항염증 치료제를 중심으로 활동하는 생물의약 기업으로, 나스닥의 최저 매수 가격 규정 준수를 성공적으로 회복했습니다. 회사는 2025년 8월 27일부터 9월 10일까지 연속 10거래일 동안 종가가 $1.00 이상을 유지했습니다.
InflaRx는 보체 활성화 인자 C5a와 그 수용체의 억제제 개발을 전문으로 합니다. 주요 제품은 vilobelimab으로, 정맥 주사로 투여되는 1차급 anti-C5a 항체이며, 함께 INF904라는 경구용 소분자 억제제도 보유하고 있습니다. 2007년에 설립된 이 회사는 독일 예나(Jena)와 뮌헨, 그리고 미국 미시간 주 애너 아버(Ann Arbor)에 사무소를 두고 있습니다.
InflaRx (NASDAQ: IFRX), une société biopharmaceutique axée sur les thérapies anti-inflammatoires, a réussi à se conformer à nouveau à l’exigence de prix d’entrée minimum de Nasdaq. L’entreprise a maintenu un cours de clôture de $1,00 ou plus pendant 10 jours ouvrables consécutifs du 27 août au 10 septembre 2025.
InflaRx se spécialise dans le développement d’inhibiteurs du facteur d’activation du complément C5a et de son récepteur. Leur produit clé est vilobelimab, un anticorps monoclonal anti-C5a administré par voie intraveineuse de première classe, aux côtés de INF904, un inhibiteur oral de petites molécules. Fondée en 2007, l’entreprise opère à partir de bureaux à Jena et Munich, en Allemagne, et à Ann Arbor, dans le Michigan.
InflaRx (NASDAQ: IFRX), ein biopharmazeutisches Unternehmen mit Fokus auf entzündungshemmende Therapeutika, hat erfolgreich die Einhaltung der Nasdaq-Anforderung an den Mindestkurswert wiedererlangt. Das Unternehmen hielt vom 27. August bis 10. September 2025 einen Schlusskurs von $1,00 oder mehr für 10 aufeinanderfolgende Handelstage.
InflaRx ist spezialisiert auf die Entwicklung von Inhibitoren des Komplementsaktivierungsfaktors C5a und seines Rezeptors. Ihr Hauptprodukt ist vilobelimab, ein klassischer intravenöser Antikörper gegen C5a, sowie INF904, ein oraler kleiner Molekül-Inhibitor. Das 2007 gegründete Unternehmen betreibt Büros in Jena und München, Deutschland, sowie in Ann Arbor, Michigan.
InflaRx (NASDAQ: IFRX)، شركة حيوية حيوية دوائية تركز على العلاجات المضادة للالتهابات، نجحت في استعادة الامتثال لمتطلبات سعر العرض الأدنى في ناسداك. حافظت الشركة على سعر إغلاق $1.00 أو أعلى لمدة 10 أيام عمل متتالية من 27 أغسطس حتى 10 سبتمبر 2025.
تتخصص InflaRx في تطوير مثبطات عامل تكوين المكمل C5a ومستقبله. منتجهم الرئيسي هو vilobelimab، وهو جسم مضاد أحادي النسيلة مضاد لـ-C5a يُعطى عبر الوريد، إلى جانب INF904، وهو مثبِّط جزيئي صغير فموي. تأسست الشركة في 2007، وتعمل بمكاتب في يينا وميونخ في ألمانيا، وفي آن أربور بولاية ميشيغان.
InflaRx (NASDAQ: IFRX)，一家专注于抗炎治疗的生物制药公司，已成功重新符合纳斯达克的最低竞价价格要求。公司在2025年8月27日至9月10日的 连续10个交易日内维持收盘价不低于 $1.00。
InflaRx 专注于开发补体活化因子 C5a 及其受体的抑制剂。其核心产品为 vilobelimab，一种静脉注射的一线抗 C5a 单克抗体，以及 INF904，一种口服小分子抑制剂。公司成立于2007年，在德国耶拿（Jena）和慕尼黑，以及美国密歇根州安娜堡设有办事处。
- Successfully regained Nasdaq listing compliance, removing delisting risk
- Demonstrated ability to maintain share price above $1.00 threshold
- Maintains diverse pipeline with both intravenous and oral drug candidates
- Recent history of stock price challenges as evidenced by previous non-compliance
- Multiple ongoing clinical programs requiring significant capital investment
Insights
InflaRx avoids Nasdaq delisting by maintaining $1+ share price for 10 consecutive days, removing a significant investor risk.
InflaRx has successfully addressed a critical regulatory challenge by regaining compliance with Nasdaq's minimum bid price requirement. The company's shares traded at
This compliance recovery is particularly significant for a biopharmaceutical company like InflaRx that's still in the development and early commercialization stages. Had the company failed to meet this requirement, it would have faced potential delisting, which typically triggers several negative consequences: reduced trading liquidity, loss of institutional investor interest (as many have mandates prohibiting investments in non-major exchange stocks), limited access to capital markets, and diminished market visibility.
The successful resolution of this compliance issue doesn't change the company's fundamental business prospects related to its C5a inhibitor technologies, but it does remove a significant technical overhang that often accelerates selling pressure. Investors can now refocus on the company's clinical and commercial progress with vilobelimab (their intravenous antibody) and INF904 (their oral small molecule inhibitor) rather than worrying about exchange status complications.
While this announcement represents an important administrative milestone that preserves InflaRx's market standing, investors should recognize that maintaining compliance will require continued vigilance regarding share price stability above the
JENA, Germany, Sept. 12, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system (the “Company”), today announced that it has received a written notice (the “Notice”), dated September 11, 2025, from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that it has regained compliance with Nasdaq’s minimum bid price requirement set forth under Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Price Requirement”).
According to the Notice, the Company regained compliance with the Minimum Bid Price Requirement because the closing bid price of the Company’s ordinary shares has been
About InflaRx N.V.
InflaRx (Nasdaq: IFRX) is a biopharmaceutical company pioneering anti-inflammatory therapeutics by applying its proprietary anti-C5a and anti-C5a receptor technologies to discover, develop and commercialize highly potent and specific inhibitors of the complement activation factor C5a and its receptor. C5a is a powerful inflammatory mediator involved in the progression of a wide variety of inflammatory diseases. InflaRx has developed vilobelimab, a novel, intravenously delivered, first-in-class, anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical studies. InflaRx is also developing INF904, an orally administered small molecule inhibitor of C5a-induced signaling via the C5a receptor.
InflaRx was founded in 2007, and the group has offices and subsidiaries in Jena and Munich, Germany, as well as Ann Arbor, MI, USA. For further information, please visit www.inflarx.de. InflaRx GmbH (Germany) and InflaRx Pharmaceuticals Inc. (USA) are wholly owned subsidiaries of InflaRx N.V. (together, InflaRx).
Contacts:
| InflaRx N.V. | MC Services AG |
| Jan Medina, CFA Vice President, Head of Investor Relations Email: IR@inflarx.de | Katja Arnold, Laurie Doyle, Dr. Regina Lutz Email: inflarx@mc-services.eu Europe: +49 89-210 2280 U.S.: +1-339-832-0752 |
FORWARD-LOOKING STATEMENTS
This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “estimate,” “believe,” “predict,” “potential” or “continue,” among others. Forward-looking statements appear in a number of places throughout this release and may include statements regarding our intentions, beliefs, projections, outlook, analyses, current expectations and the risks, uncertainties and other factors described under the headings, “Risk factors” and “Cautionary statement regarding forward looking statements”, in our periodic filings with the SEC. These statements speak only as of the date of this press release and involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future, except as required by law.
FAQ
When did InflaRx (IFRX) regain Nasdaq compliance?
What is InflaRx's main product pipeline?
What was the minimum bid price requirement that IFRX needed to meet?
Where is InflaRx headquartered?
